Illuminating Heavy Metals Testing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Illuminating Heavy Metals Testing
USP <231> Heavy Metals is transitioning toward the incorporation of modern quantitative technologies, but there is still much to be resolved.


Pharmaceutical Technology
Volume 33, Issue 2, pp. 36-42


(ILLUSTRATION: M.MCEVOY IMAGES: CASPER BENSON, DAVID FREUND/GETTY IMAGES)
A stimuli article calling for revised methods for detecting heavy metals impurities in drug substances and drug products has been applauded for addressing an issue long overdue and has prompted much needed discussion (1). While the details of the article replacing the nearly 100-year-old USPNF (231) Heavy Metals General Chapter are debated, industry and regulators are actively keeping an eye on its progress. The final chapter will affect makers of drug substances, finished drug products, and raw materials. Factors under consideration include the types of impurities that should be detected, their acceptance limits, and the analytical tools for quantitative assessment.

Impurity detection has received heightened attention since the scandals involving lead in toys, glycerin contamination with diethylene glycol, adulterated heparin, and melamine in pet food and infant formula. A strong impurities screening approach is especially important as an increasing amount of drug substances and excipients are imported from regions outside of the United States. "When FDA has to confront these big problems, it has to start using all the tools at its disposal. Eventually manufacturers will have to know more about what they buy," says Luciano Virgili, former director of global testing standards at Bristol Meyers Squibb.

Problems with current methodology

The USP ‹231› General Chapter screening methods are outdated, nonspecific, and, for the most part, inefficient. The qualitative wet chemistry techniques convert metals to a sulfide and analysts compare the colors of the sample liquid to a standard preparation to determine whether metallic impurities are present. The chapter contains three methods. Method I is used for substances that yield a colorless liquid preparation and involves only dissolving and diluting the substance. Methods II and III, however, are used for substances that do not yield colorless preparations and involve heating the substance, which may result in the loss of some metals and negatively impact the accuracy of the analysis.

"The way the method is run, you can detect 10 different metals while performing the test," says Gayla Velez, director of analytical services at SGS Northview Labs (Northbrook, IL). "But when USP revised the General Chapter a few years ago and they added a monitor to Method II, we found you couldn't recover most of those metals if you spiked it, and then took it through the digestion process. So what concerns me is that we are doing this test on a day-to-day basis, yet we know that we may be losing some of the metals that we are trying to detect."

Industry analysts have reported difficulty with reagents and achieving results with the monitor solutions and standards (2). Moreover, the methods in the current chapter are nonspecific. "One description of it is hitting two rocks together and hoping it's going to tell you the right answer," says Steve Boyajian, business development manager at Activation Labs (Ancaster, Ontario). "You very rarely, if ever, get a positive result from the current test indicating there is metal above the limit. Even if a problem existed, the current test would not be able to detect it."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here